{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=eribulin+mesylate&page=2", "query": { "intervention": "eribulin mesylate", "page": 2 }, "page_size": 10 }, "pagination": { "page": 2, "page_size": 10, "total_count": 10, "total_pages": 1, "next_page_url": null, "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=eribulin+mesylate&page=1&page_size=10" }, "source": "remote", "last_synced_at": "2026-09-28T21:28:05.368Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT02097238", "title": "Eribulin Mesylate in Treating Patients With Recurrent or Refractory Osteosarcoma", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Recurrent Osteosarcoma" ], "interventions": [ { "name": "Eribulin Mesylate", "type": "DRUG" }, { "name": "Pharmacological Study", "type": "OTHER" } ], "intervention_types": [ "DRUG", "OTHER" ], "sponsor": "National Cancer Institute (NCI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "12 Years", "maximum_age": "49 Years", "sex": "ALL", "summary": "12 Years to 49 Years" }, "enrollment_count": 19, "start_date": "2014-08", "completion_date": "2020-03-31", "has_results": true, "last_update_posted_date": "2020-05-19", "last_synced_at": "2026-09-28T21:28:05.368Z", "location_count": 116, "location_summary": "Birmingham, Alabama • Phoenix, Arizona • Downey, California + 76 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Phoenix", "state": "Arizona" }, { "city": "Downey", "state": "California" }, { "city": "Loma Linda", "state": "California" }, { "city": "Los Angeles", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT02097238" }, { "nct_id": "NCT03331250", "title": "Eribulin in Angiosarcoma and Epithelioid Hemangioendothelioma (EHE)", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Angiosarcoma", "Epithelioid Hemangioendothelioma" ], "interventions": [ { "name": "Eribulin", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Massachusetts General Hospital", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 13, "start_date": "2018-01-18", "completion_date": "2023-05-23", "has_results": true, "last_update_posted_date": "2026-08-28", "last_synced_at": "2026-09-28T21:28:05.368Z", "location_count": 2, "location_summary": "Boston, Massachusetts", "locations": [ { "city": "Boston", "state": "Massachusetts" }, { "city": "Boston", "state": "Massachusetts" } ], "official_url": "https://clinicaltrials.gov/study/NCT03331250" }, { "nct_id": "NCT00334893", "title": "Eribulin Mesylate in Treating Patients With Recurrent Ovarian Epithelial, Primary Peritoneal Cavity, or Fallopian Tube Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Fallopian Tube Cancer", "Primary Peritoneal Cavity Cancer", "Recurrent Ovarian Epithelial Cancer" ], "interventions": [ { "name": "eribulin mesylate", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "National Cancer Institute (NCI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "FEMALE", "summary": "18 Years and older · Female only" }, "enrollment_count": 74, "start_date": "2006-04", "completion_date": "2012-03", "has_results": true, "last_update_posted_date": "2017-11-29", "last_synced_at": "2026-09-28T21:28:05.368Z", "location_count": 2, "location_summary": "Boston, Massachusetts • New York, New York", "locations": [ { "city": "Boston", "state": "Massachusetts" }, { "city": "New York", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT00334893" }, { "nct_id": "NCT01676818", "title": "Eribulin Mesylate in Treating Patients With Advanced or Recurrent Cervical Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Recurrent Cervical Cancer", "Stage IIIA Cervical Cancer", "Stage IIIB Cervical Cancer", "Stage IVA Cervical Cancer", "Stage IVB Cervical Cancer" ], "interventions": [ { "name": "eribulin mesylate", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "University of Southern California", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "FEMALE", "summary": "18 Years and older · Female only" }, "enrollment_count": 32, "start_date": "2012-08-09", "completion_date": "2021-12-22", "has_results": true, "last_update_posted_date": "2025-11-06", "last_synced_at": "2026-09-28T21:28:05.368Z", "location_count": 1, "location_summary": "Los Angeles, California", "locations": [ { "city": "Los Angeles", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT01676818" }, { "nct_id": "NCT03051659", "title": "A Randomized Phase II Study Of Eribulin Mesylate With or Without Pembrolizumab For Metastatic Hormone Receptor Positive Breast Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Breast Cancer" ], "interventions": [ { "name": "Eribulin Mesylate", "type": "DRUG" }, { "name": "Pembrolizumab", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Dana-Farber Cancer Institute", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 90, "start_date": "2017-03-22", "completion_date": "2023-09-05", "has_results": true, "last_update_posted_date": "2024-03-06", "last_synced_at": "2026-09-28T21:28:05.368Z", "location_count": 3, "location_summary": "Boston, Massachusetts", "locations": [ { "city": "Boston", "state": "Massachusetts" }, { "city": "Boston", "state": "Massachusetts" }, { "city": "Boston", "state": "Massachusetts" } ], "official_url": "https://clinicaltrials.gov/study/NCT03051659" }, { "nct_id": "NCT01613768", "title": "Eribulin Mesylate in Treating Patients With Recurrent or Metastatic Salivary Gland Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Recurrent Salivary Gland Cancer", "Stage IVA Salivary Gland Cancer", "Stage IVB Salivary Gland Cancer", "Stage IVC Salivary Gland Cancer" ], "interventions": [ { "name": "eribulin mesylate", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "University of Washington", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 29, "start_date": "2012-05-08", "completion_date": "2017-08-23", "has_results": true, "last_update_posted_date": "2018-09-28", "last_synced_at": "2026-09-28T21:28:05.368Z", "location_count": 1, "location_summary": "Seattle, Washington", "locations": [ { "city": "Seattle", "state": "Washington" } ], "official_url": "https://clinicaltrials.gov/study/NCT01613768" }, { "nct_id": "NCT02338037", "title": "Neuropharmacokinetics of Eribulin Mesylate in Treating Patients With Primary or Metastatic Brain Tumors", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "EARLY_PHASE1" ], "conditions": [ "Metastatic Malignant Neoplasm in the Adult Brain", "Primary Brain Tumor" ], "interventions": [ { "name": "Therapeutic Conventional Surgery", "type": "PROCEDURE" }, { "name": "Biopsy", "type": "PROCEDURE" }, { "name": "Eribulin Mesylate", "type": "DRUG" }, { "name": "Microdialysis", "type": "PROCEDURE" }, { "name": "Pharmacological Study", "type": "OTHER" } ], "intervention_types": [ "PROCEDURE", "DRUG", "OTHER" ], "sponsor": "City of Hope Medical Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 8, "start_date": "2015-05-19", "completion_date": "2024-03-15", "has_results": false, "last_update_posted_date": "2024-03-19", "last_synced_at": "2026-09-28T21:28:05.368Z", "location_count": 1, "location_summary": "Duarte, California", "locations": [ { "city": "Duarte", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT02338037" }, { "nct_id": "NCT04345913", "title": "Testing the Addition of Copanlisib to Eribulin in Metastatic Triple Negative Breast Cancer", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Anatomic Stage III Breast Cancer AJCC v8", "Anatomic Stage IV Breast Cancer AJCC v8", "Metastatic Triple-Negative Breast Carcinoma", "Unresectable Triple-Negative Breast Carcinoma" ], "interventions": [ { "name": "Biopsy Procedure", "type": "PROCEDURE" }, { "name": "Biospecimen Collection", "type": "PROCEDURE" }, { "name": "Computed Tomography", "type": "PROCEDURE" }, { "name": "Copanlisib Hydrochloride", "type": "DRUG" }, { "name": "Eribulin Mesylate", "type": "DRUG" }, { "name": "Magnetic Resonance Imaging", "type": "PROCEDURE" } ], "intervention_types": [ "PROCEDURE", "DRUG" ], "sponsor": "National Cancer Institute (NCI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 24, "start_date": "2021-03-01", "completion_date": "2027-05-31", "has_results": true, "last_update_posted_date": "2026-07-31", "last_synced_at": "2026-09-28T21:28:05.368Z", "location_count": 43, "location_summary": "Sacramento, California • Derby, Connecticut • Fairfield, Connecticut + 34 more", "locations": [ { "city": "Sacramento", "state": "California" }, { "city": "Derby", "state": "Connecticut" }, { "city": "Fairfield", "state": "Connecticut" }, { "city": "Glastonbury", "state": "Connecticut" }, { "city": "Greenwich", "state": "Connecticut" } ], "official_url": "https://clinicaltrials.gov/study/NCT04345913" }, { "nct_id": "NCT02000596", "title": "1303GCC: Trastuzmab & Pertuzumab With Hormonal Therapy or Chemotherapy in Women Aged 60 and Over.", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Metastatic Breast Cancer" ], "interventions": [ { "name": "Trastuzumab plus Pertuzumab", "type": "DRUG" }, { "name": "Hormonal Therapy with Anastrozole and Fulvestrant", "type": "DRUG" }, { "name": "Chemotherapy with Eribulin", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "University of Maryland, Baltimore", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "60 Years", "maximum_age": null, "sex": "FEMALE", "summary": "60 Years and older · Female only" }, "enrollment_count": 2, "start_date": "2014-01", "completion_date": "2016-01", "has_results": true, "last_update_posted_date": "2022-05-27", "last_synced_at": "2026-09-28T21:28:05.368Z", "location_count": 1, "location_summary": "Baltimore, Maryland", "locations": [ { "city": "Baltimore", "state": "Maryland" } ], "official_url": "https://clinicaltrials.gov/study/NCT02000596" }, { "nct_id": "NCT00337103", "title": "E7389 Versus Capecitabine in Patients With Locally Advanced or Metastatic Breast Cancer Previously Treated With Anthracyclines and Taxanes", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Metastatic Breast Cancer" ], "interventions": [ { "name": "Eribulin Mesylate", "type": "DRUG" }, { "name": "Capecitabine", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Eisai Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "FEMALE", "summary": "18 Years and older · Female only" }, "enrollment_count": 1276, "start_date": "2006-09-20", "completion_date": "2017-12-11", "has_results": true, "last_update_posted_date": "2020-06-18", "last_synced_at": "2026-09-28T21:28:05.368Z", "location_count": 13, "location_summary": "Anaheim, California • La Verne, California • Poway, California + 10 more", "locations": [ { "city": "Anaheim", "state": "California" }, { "city": "La Verne", "state": "California" }, { "city": "Poway", "state": "California" }, { "city": "Centralia", "state": "Illinois" }, { "city": "Augusta", "state": "Maine" } ], "official_url": "https://clinicaltrials.gov/study/NCT00337103" } ] }